JOP20210035A1 - توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns - Google Patents

توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns

Info

Publication number
JOP20210035A1
JOP20210035A1 JOP/2021/0035A JOP20210035A JOP20210035A1 JO P20210035 A1 JOP20210035 A1 JO P20210035A1 JO P20210035 A JOP20210035 A JO P20210035A JO P20210035 A1 JOP20210035 A1 JO P20210035A1
Authority
JO
Jordan
Prior art keywords
drug
salt
reuptake inhibitor
antidepressant
brexpiprazole
Prior art date
Application number
JOP/2021/0035A
Other languages
English (en)
Inventor
Maeda Kenji
Kikuchi Tetsuro
Toda Masafumi
Hirose Tsuyoshi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46045045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20210035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of JOP20210035A1 publication Critical patent/JOP20210035A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Abstract

يتعلق الاختراع الحالي بدواء له نطاق علاجي أوسع، ويتسبب في آثار جانبية أقل ويكون أقوى من حيث التحمل والأمان، مقارنةً بالعوامل المضادة للذهان النمطية المعروفة والعوامل المضادة للذهان غير النمطية. يتعلق الاختراع الحالي بدواء يشتمل على (1) مركب يتمثل في 7-[4-(4-بنزو[b]ثيوفين-4-يل-بيبرازين-1-يل)بيوتوكسي]-1H-كينولين-2-أون أو ملح منه، و(2) عقار واحد على الأقل يتم اختياره من المجموعة المؤلفة من مثبت الحالة المزاجية، مثبط إعادة امتصاص السيرُوتُونين، مثبط إعادة امتصاص النورأَبِينِفْرين، مثبط إعادة امتصاص السيرُوتُونين والنورأَبِينِفْرين، مضاد للاكتئاب نُورأَدْرينيّ وسيروتونيني التأثير نوعي، عقار مضاد للقلق، مضاد للاكتئاب ثلاثي الحلقة، مضاد للاكتئاب رباعي الحلقة، وعقار مضاد للذهان وعقار مضاد لـ ADHD، في توليفة.
JOP/2021/0035A 2011-04-05 2021-02-25 توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns JOP20210035A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471911P 2011-04-05 2011-04-05
US201161580540P 2011-12-27 2011-12-27

Publications (1)

Publication Number Publication Date
JOP20210035A1 true JOP20210035A1 (ar) 2023-01-30

Family

ID=46045045

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2012/0083A JOP20120083B1 (ar) 2011-04-05 2012-04-03 توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
JOP/2021/0035A JOP20210035A1 (ar) 2011-04-05 2021-02-25 توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JOP/2012/0083A JOP20120083B1 (ar) 2011-04-05 2012-04-03 توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns

Country Status (31)

Country Link
US (5) US20140120185A1 (ar)
EP (4) EP2694043B1 (ar)
JP (2) JP5992924B2 (ar)
KR (1) KR101890450B1 (ar)
CN (2) CN108042808B (ar)
AR (1) AR085840A1 (ar)
AU (1) AU2012240864B2 (ar)
BR (1) BR112013025420B1 (ar)
CA (1) CA2832157C (ar)
CO (1) CO6801769A2 (ar)
CY (1) CY1120567T1 (ar)
DK (1) DK2694043T3 (ar)
EA (1) EA035837B1 (ar)
ES (1) ES2654851T3 (ar)
HK (1) HK1246159A1 (ar)
HR (1) HRP20180098T1 (ar)
HU (1) HUE035542T2 (ar)
IL (1) IL228669B (ar)
JO (2) JOP20120083B1 (ar)
LT (1) LT2694043T (ar)
MX (2) MX370670B (ar)
MY (1) MY166936A (ar)
NZ (1) NZ615591A (ar)
PL (1) PL2694043T3 (ar)
PT (1) PT2694043T (ar)
RS (1) RS56802B1 (ar)
SG (2) SG10201602326RA (ar)
SI (1) SI2694043T1 (ar)
TW (1) TWI636784B (ar)
WO (1) WO2012137971A1 (ar)
ZA (1) ZA201306981B (ar)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
SG11201608766TA (en) 2014-04-22 2016-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
WO2015188092A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
AU2017240259A1 (en) 2016-04-01 2018-10-18 Upmc Regulatory device and associated method
US11123300B2 (en) 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
EP3500249A1 (en) 2016-08-16 2019-06-26 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
DK3532064T3 (da) * 2016-10-28 2020-08-24 H Lundbeck As Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3501506B1 (en) * 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
JP6831354B2 (ja) * 2018-08-16 2021-02-17 株式会社Ｄｎｐファインケミカル 接着性組成物からなる錠剤、その製造方法、及び該錠剤を用いた部材又は部品の製造方法
JP2019183095A (ja) * 2018-08-16 2019-10-24 株式会社Ｄｎｐファインケミカル 接着性粉体、接着性錠剤の製造方法、接着性錠剤、並びに該接着性粉体及び錠剤を用いた部材又は部品の製造方法
BR112021007745A2 (pt) * 2018-10-24 2021-07-27 Effector Therapeutics, Inc. formas cristalinas de inibidores de mnk
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
TW202103699A (zh) 2019-04-17 2021-02-01 英商康派斯百事威公司 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）於憂鬱及其他各種失調症之治療
JPWO2021029020A1 (ar) * 2019-08-13 2021-02-18
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN113322299A (zh) * 2021-05-28 2021-08-31 南昌大学 一种抑郁症和药物成瘾疾病的药物靶点识别方法
US20240009181A1 (en) * 2022-07-08 2024-01-11 Jason Eric Schiffman Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US20040176466A1 (en) * 2001-08-08 2004-09-09 Allen Albert John Combination therapy for the treatment of neurological disorders
MXPA05006857A (es) * 2002-12-27 2005-08-18 Otsuka Pharma Co Ltd Derivados de carbostirilo e inhibidores de la recaptacion de serotonina para el tratamiento de desordenes en el humor.
CA2601716C (en) * 2004-06-25 2011-05-31 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
DE602007010818D1 (de) * 2006-10-27 2011-01-05 Janssen Pharmaceutica Nv Verfahren zur behandlung disruptiver verhaltensstörungen
JP2008189616A (ja) * 2007-02-07 2008-08-21 Mitsubishi Tanabe Pharma Corp 注意欠陥多動性障害の治療薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物

Also Published As

Publication number Publication date
SG10201602326RA (en) 2016-04-28
US20140120185A1 (en) 2014-05-01
CO6801769A2 (es) 2013-11-29
MY166936A (en) 2018-07-25
TWI636784B (zh) 2018-10-01
JP2017031155A (ja) 2017-02-09
CA2832157C (en) 2023-06-27
US20180042923A1 (en) 2018-02-15
HUE035542T2 (hu) 2018-05-02
MX370670B (es) 2019-12-19
EA201391450A1 (ru) 2014-03-31
IL228669A0 (en) 2013-12-31
JOP20120083B1 (ar) 2021-08-17
NZ615591A (en) 2016-02-26
WO2012137971A1 (en) 2012-10-11
IL228669B (en) 2020-04-30
SG193468A1 (en) 2013-10-30
RS56802B1 (sr) 2018-04-30
EP2694043A1 (en) 2014-02-12
JP2014510023A (ja) 2014-04-24
JP5992924B2 (ja) 2016-09-14
EP2694043B1 (en) 2017-11-01
ZA201306981B (en) 2014-05-28
BR112013025420A2 (pt) 2016-12-27
CN103547260B (zh) 2019-08-13
US20170100395A1 (en) 2017-04-13
AR085840A1 (es) 2013-10-30
EP4023223A1 (en) 2022-07-06
HK1246159A1 (zh) 2018-09-07
PL2694043T3 (pl) 2018-04-30
TW201311242A (zh) 2013-03-16
DK2694043T3 (en) 2018-01-15
ES2654851T3 (es) 2018-02-15
SI2694043T1 (en) 2018-03-30
CN108042808A (zh) 2018-05-18
BR112013025420B1 (pt) 2021-10-13
LT2694043T (lt) 2018-02-12
CA2832157A1 (en) 2012-10-11
US20220000861A1 (en) 2022-01-06
KR101890450B1 (ko) 2018-08-21
AU2012240864B2 (en) 2017-02-02
EA035837B1 (ru) 2020-08-19
CY1120567T1 (el) 2019-07-10
CN108042808B (zh) 2021-02-09
EP3626243A1 (en) 2020-03-25
MX2019015237A (es) 2020-02-13
PT2694043T (pt) 2018-01-16
AU2012240864A1 (en) 2013-11-07
EP3299018A1 (en) 2018-03-28
HRP20180098T1 (hr) 2018-03-23
CN103547260A (zh) 2014-01-29
MX2013010796A (es) 2013-12-06
KR20140021648A (ko) 2014-02-20
US20180325894A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
JOP20210035A1 (ar) توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
EA201171493A1 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
JO3421B1 (ar) طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
MX371279B (es) Agente profiláctico y/o terapéutico para síntomas conductuales y psicológicos asociados con la enfermedad neurodegenerativa o síntomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo.
EA201790267A1 (ru) Новые модуляторы киназ
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
EA201201193A1 (ru) Тиенопиримидины, содержащие гетероциклоалкил, предназначенные для фармацевтических композиций
IN2014DN09804A (ar)
EA201491933A1 (ru) Дигидрат соединения бензотиофена или его соли и способ его получения
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
EA201201192A1 (ru) Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
SG195106A1 (en) Trpv4 antagonists
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
EA201201201A1 (ru) Новые ингибиторы rock
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
MD4538B1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
MX2010004315A (es) Compuestos para inhibir la actividad de quinesina ksp.
MX2010004313A (es) Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso.
PH12015501230A1 (en) Finafloxacin suspension compositions
GEP201706657B (en) Quinoline derivatives as pde10a enzyme inhibitors
TH151403A (th) ตัวยารวมซึ่งประกอบรวมด้วยเบรกซ์พิแพรโซลหรือเกลือของสารนั้น และยาชนิดที่สองสำหรับใช้ในการรักษาโรคของ cns